Advertisement
Original Research Article|Articles in Press

Perioperative use of NSAIDs and the risk of short-term endoscopic recurrence in Crohn's disease patients: A retrospective cohort study

Published:December 07, 2022DOI:https://doi.org/10.1016/j.amjsurg.2022.12.003

      Highlights

      • Perioperative use of NSAIDs was not associated with an increased risk of endoscopic disease recurrence after ileocolectomy.
      • There was no difference in clinical recurrence rates between those exposed and non-exposed to NSAIDs.
      • NSAIDs appear to be safe to use as part of an accelerated pathway for recovery following surgery for CD.

      Abstract

      Background

      More evidence is needed on the use of NSAID based postoperative pain regimens for Crohn's disease (CD) and its association with recurrence. Our goal is to assess the impact of perioperative use of NSAIDs on endoscopic disease recurrence in patients with CD.

      Methods

      A retrospective cohort study was conducted. The primary outcome measured was endoscopic disease recurrence within 24 months of surgery, defined as a Rutgeerts score ≥ i2.

      Results

      We identified 107 patients with CD that underwent index ileocolectomy with primary anastomosis between January 2009 and July 2019. Endoscopic disease recurrence was identified in 28 (26.2%) and clinical recurrence in 18 (16.8%) patients. Exposure to NSAIDs did not increase 24-month endoscopic recurrence risk (22.2% vs. 38.5% patients, p = 0.12).

      Conclusion

      In patients with CD undergoing elective ileocolic resection and primary ileocolic anastomosis, NSAID use in the perioperative period did not impact endoscopic or clinical disease recurrence rate.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Papadakis K.A.
        • Tabibzadeh S.
        Diagnosis and misdiagnosis of inflammatory bowel disease.
        Gastrointest Endosc Clin N Am. 2002; 12: 433-449https://doi.org/10.1016/S1052-5157(02)00005-3
        • Podolsky D.K.
        Inflammatory bowel disease.
        N Engl J Med. 2002; 347: 417-429https://doi.org/10.1056/NEJMra020831
        • Toh J.W.T.
        • Wang N.
        • Young C.J.
        • et al.
        Major abdominal and perianal surgery in Crohn's disease: long-term follow-up of Australian patients with Crohn's disease.
        Dis Colon Rectum. 2018; 61: 67-76https://doi.org/10.1097/DCR.0000000000000975
        • de Buck van Overstraeten A.
        • Eshuis E.J.
        • Vermeire S.
        • et al.
        Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres.
        Br J Surg. 2017; 104: 1713-1722https://doi.org/10.1002/bjs.10595
        • Rutgeerts P.
        • Geboes K.
        • Vantrappen G.
        • et al.
        Predictability of the postoperative course of Crohn's disease.
        Gastroenterology. 1990; 99: 956-963https://doi.org/10.1016/0016-5085(90)90613-6
        • De Cruz P.
        • Kamm M.A.
        • Hamilton A.L.
        • et al.
        Crohn's disease management after intestinal resection: a randomised trial.
        Lancet. 2015; 385: 1406-1417https://doi.org/10.1016/S0140-6736(14)61908-5
        • Cryer B.
        NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality.
        Am J Gastroenterol. 2005; 100: 1694-1695https://doi.org/10.1111/j.1572-0241.2005.50565.x
        • Wolfe M.M.
        • Lichtenstein D.R.
        • Singh G.
        Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
        N Engl J Med. 1999; 340: 1888-1899https://doi.org/10.1056/NEJM199906173402407
        • Cashman J.N.
        The mechanisms of action of NSAIDs in analgesia.
        in: Drugs. vol. 52. Springer International Publishing, 1996: 13-23https://doi.org/10.2165/00003495-199600525-00004
        • Sostres C.
        • Gargallo C.J.
        • Arroyo M.T.
        • et al.
        Adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.
        Best Pract Res Clin Gastroenterol. 2010; 24: 121-132https://doi.org/10.1016/j.bpg.2009.11.005
        • Takeuchi K.
        • Smale S.
        • Premchand P.
        • et al.
        Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.
        Clin Gastroenterol Hepatol. 2006; 4: 196-202https://doi.org/10.1016/S1542-3565(05)00980-8
        • Guslandi M.
        Exacerbation of inflammatory bowel disease by nonsterioidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction?.
        World J Gastroenterol. 2006; 12: 1509-1510https://doi.org/10.3748/wjg.v12.i10.1509
        • Wallace J.L.
        Prostaglandin biology in inflammatory bowel disease.
        Gastroenterol Clin North Am. 2001; 30: 971-980https://doi.org/10.1016/S0889-8553(05)70223-5
        • Meyer A.M.
        • Ramzan N.N.
        • Heigh R.I.
        • et al.
        Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs.
        Dig Dis Sci. 2006; 51: 168-172https://doi.org/10.1007/s10620-006-3103-5
        • Maiden L.
        • Thjodleifsson B.
        • Theodors A.
        • et al.
        A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy.
        Gastroenterology. 2005; 128: 1172-1178https://doi.org/10.1053/j.gastro.2005.03.020
        • Tanaka K.-I.
        • Suemasu S.
        • Ishihara T.
        • et al.
        Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for nonsteroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
        Eur J Pharmacol. 2009; 603: 120-132https://doi.org/10.1016/j.ejphar.2008.11.058
        • Tsubouchi R.
        • Hayashi S.
        • Aoi Y.
        • et al.
        Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats.
        Digestion. 2007; 74: 91-100https://doi.org/10.1159/000097657
        • Bonner G.F.
        • Fakhri A.
        • Vennamanemi S.R.
        A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease.
        Inflamm Bowel Dis. 2004; 10: 751-757https://doi.org/10.1097/00054725-200411000-00009
        • El Miedany Y.
        • Youssef S.
        • Ahmed I.
        • et al.
        The gastrointestinal safety and effect on disease activity of etoricoxib, a selective Cox-2 inhibitor in inflammatory bowel diseases.
        Am J Gastroenterol. 2006; 101: 311-317https://doi.org/10.1111/j.1572-0241.2006.00384.x
        • Sandborn W.J.
        • Stenson W.F.
        • Brynskov J.
        • et al.
        Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.
        Clin Gastroenterol Hepatol. 2006; 4: 203-211https://doi.org/10.1016/j.cgh.2005.12.002
        • Renna S.
        • Cammà C.
        • Modesto I.
        • et al.
        Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease.
        Gastroenterology. 2008; 135: 1500-1509https://doi.org/10.1053/j.gastro.2008.07.066
        • Hawkins A.T.
        • McEvoy M.D.
        • Wanderer J.P.
        • et al.
        Ketorolac use and anastomotic leak in elective colorectal surgery: a detailed analysis.
        in: Diseases of the Colon and Rectum. vol. 61. Lippincott Williams and Wilkins, 2018: 1426-1434https://doi.org/10.1097/DCR.0000000000001244
        • Cottone M.
        • Orlando A.
        • Modesto I.
        Postoperative maintenance therapy for inflammatory bowel disease.
        Curr Opin Gastroenterol. 2006; 22: 377-381https://doi.org/10.1097/01.mog.0000231811.95525.7c
        • Buisson A.
        • Chevaux J.B.
        • Allen P.B.
        • et al.
        Review article: the natural history of postoperative Crohn's disease recurrence.
        Aliment Pharmacol Ther. 2012; 35: 625-633https://doi.org/10.1111/j.1365-2036.2012.05002.x
        • De Cruz P.
        • Kamm M.A.
        • Prideaux L.
        • et al.
        Postoperative recurrent luminal Crohn's disease: a systematic review.
        Inflamm Bowel Dis. 2012; https://doi.org/10.1002/ibd.21825
        • D'Haens G.R.
        • Vermeire S.
        • Van Assche G.
        • et al.
        Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial.
        Gastroenterology. 2008; 135: 1123-1129https://doi.org/10.1053/j.gastro.2008.07.010
        • Reese G.E.
        • Nanidis T.
        • Borysiewicz C.
        • et al.
        The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies.
        Int J Colorectal Dis. 2008; 23: 1213-1221https://doi.org/10.1007/s00384-008-0542-9
        • To N.
        • Gracie D.J.
        • Ford A.C.
        Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease.
        Aliment Pharmacol Ther. 2016; 43: 549-561https://doi.org/10.1111/apt.13511
        • Biancone L.
        • Tosti C.
        • Geremia A.
        • et al.
        Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.
        Aliment Pharmacol Ther. 2004; 19: 755-764https://doi.org/10.1111/j.1365-2036.2004.01907.x
        • Bonner G.F.
        Exacerbation of inflammatory bowel disease associated with use of celecoxib.
        Am J Gastroenterol. 2001; 96: 1306-1308https://doi.org/10.1111/j.1572-0241.2001.03730.x
        • Moninuola O.O.
        • Milligan W.
        • Lochhead P.
        • et al.
        Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.
        Aliment Pharmacol Ther. 2018; 47: 1428-1439https://doi.org/10.1111/apt.14606
        • Kono T.
        • Fichera A.
        • Maeda K.
        • et al.
        Kono-S anastomosis for surgical prophylaxis of anastomotic recurrence in Crohn's disease: an international multicenter study.
        J Gastrointest Surg. 2016; 20: 783-790https://doi.org/10.1007/s11605-015-3061-3
        • Alshantti A.
        • Hind D.
        • Hancock L.
        • Brown S.R.
        The role of Kono-S anastomosis and mesenteric resection in reducing recurrence after surgery for Crohn's disease: a systematic review.
        Colorectal Dis. 2021; 23: 7-17https://doi.org/10.1111/codi.15136